Slovacia - slovacă - ŠÚKL (Štátny ústav pre kontrolu liečiv)

fresenius kabi s.r.o., Česká republika - sacharidy - 76 - infundibilia

Slovacia - slovacă - ŠÚKL (Štátny ústav pre kontrolu liečiv)

medigroup s.r.o., slovensko - iné imunostimulanciá (zmena who) - 59 - immunopraeparata

Slovacia - slovacă - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ratiopharm gmbh, nemecko - formoterol - 14 - bronchodilatantia, antiasthmatica

Slovacia - slovacă - Ústav štátnej kontroly veterinárnych biopreparátov a liečiv

bioveta, Česká republilka - inj.

Slovacia - slovacă - Ústav štátnej kontroly veterinárnych biopreparátov a liečiv

vetservis, slovenská republika - inj.

Slovacia - slovacă - Ústav štátnej kontroly veterinárnych biopreparátov a liečiv

boehringer ingelheim vetmedica, srn - gran.

Slovacia - slovacă - ŠÚKL (Štátny ústav pre kontrolu liečiv)

linde gas a.s., Česká republika - medicinálny vzduch - 87 - varia i

Uniunea Europeană - slovacă - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmologiká - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Uniunea Europeană - slovacă - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologiká - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Uniunea Europeană - slovacă - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologiká - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).